File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Engineered Tandem Bispecific Neutralising Antibody for HIV-1 Prevention and Immunotherapy
| Title | Engineered Tandem Bispecific Neutralising Antibody for HIV-1 Prevention and Immunotherapy |
|---|---|
| Authors | |
| Issue Date | 2018 |
| Citation | HIV Research for Prevention 2018 (HIVR4P 2018), Madrid, Spain, 21-25 October 2018 How to Cite? |
| Abstract | In this study, we investigated the potential of an engineered tandem bispecific broadly neutralizing antibody (bs-bNAb) as an innovative product for HIV-1 prophylactic and therapeutic interventions. We discovered that by preserving two scFv binding domains of each parental bNAb, a single-gene encoded tandem bs-bNAb, namely BiIA-SG, displayed significantly improved breadth and potency by neutralizing all HIV-1 pseudotyped viruses tested, including global subtypes/recombinant forms, transmitted/founder viruses, and variants less or not susceptible to parental and many bNAbs. In humanized mice and rhesus monkeys, an injection of BiIA-SG conferred sterile protection when administered prior to challenges with diverse live HIV-1 and SHIV, respectively. Moreover, BiIA-SG displayed immunotherapeutic efficacy in humanized mice and SHIV/macaques models. Our results warrant the clinical development of BiIA-SG as a promising bs-bNAb-based biomedical intervention for HIV-1 prevention and immunotherapy. (We acknowledge HK TRS T11-706/18-N for support.) |
| Description | Symposium SY01 We Want bNAbs: Passively Infused and Induced by Vaccines - no. SY01.01 |
| Persistent Identifier | http://hdl.handle.net/10722/272034 |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Chen, Z | - |
| dc.date.accessioned | 2019-07-20T10:34:22Z | - |
| dc.date.available | 2019-07-20T10:34:22Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.citation | HIV Research for Prevention 2018 (HIVR4P 2018), Madrid, Spain, 21-25 October 2018 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/272034 | - |
| dc.description | Symposium SY01 We Want bNAbs: Passively Infused and Induced by Vaccines - no. SY01.01 | - |
| dc.description.abstract | In this study, we investigated the potential of an engineered tandem bispecific broadly neutralizing antibody (bs-bNAb) as an innovative product for HIV-1 prophylactic and therapeutic interventions. We discovered that by preserving two scFv binding domains of each parental bNAb, a single-gene encoded tandem bs-bNAb, namely BiIA-SG, displayed significantly improved breadth and potency by neutralizing all HIV-1 pseudotyped viruses tested, including global subtypes/recombinant forms, transmitted/founder viruses, and variants less or not susceptible to parental and many bNAbs. In humanized mice and rhesus monkeys, an injection of BiIA-SG conferred sterile protection when administered prior to challenges with diverse live HIV-1 and SHIV, respectively. Moreover, BiIA-SG displayed immunotherapeutic efficacy in humanized mice and SHIV/macaques models. Our results warrant the clinical development of BiIA-SG as a promising bs-bNAb-based biomedical intervention for HIV-1 prevention and immunotherapy. (We acknowledge HK TRS T11-706/18-N for support.) | - |
| dc.language | eng | - |
| dc.relation.ispartof | HIV Research for Prevention 2018 (HIVR4P 2018) | - |
| dc.title | Engineered Tandem Bispecific Neutralising Antibody for HIV-1 Prevention and Immunotherapy | - |
| dc.type | Conference_Paper | - |
| dc.identifier.email | Chen, Z: zchenai@hku.hk | - |
| dc.identifier.authority | Chen, Z=rp00243 | - |
| dc.identifier.hkuros | 298719 | - |